Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript Summary
Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript Summary
Gross margin for Life Sciences Services improved to 46%.The following is a summary of the Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript:
以下是Cryoport公司（CYRX）2024年第三季度業績會交易摘要：
Financial Performance:
財務表現:
Cryoport reported revenue growth in their Life Sciences Services business by 9% in Q3, with BioStorage and BioServices revenue up by over 12% from the previous year.
The company maintained its full-year revenue guidance between $225 million and $235 million.
Gross margin for Life Sciences Services improved to 46%.
The company achieved positive cash flow and an improvement in adjusted EBITDA during the quarter.
Cryoport報告其生命科學服務業務在第三季度實現了9%的營業收入增長，其中BioStorage和BioServices的營業收入較去年同期增長超過12%。
公司將全年營業收入指引維持在22500萬至23500萬之間。
生命科學服務的毛利率提高到46%。
公司在本季度實現了正現金流和調整後的EBITDA改善。
Business Progress:
業務進展:
Cryoport launched the IntegriCell cryopreservation solution, a part of its expanding cryopreservation services, alongside opening a new state-of-the-art facility in Houston.
The newly operational CRYOGENE biorepository in San Antonio commenced operation, serving its first major cord blood repository client.
The company continues to gain traction with nine high-value contracts awarded during Q3 worth over $6 million annually.
Cryoport推出了IntegriCell冷凍保存解決方案，作爲其不斷擴大的冷凍保存服務的一部分，同時在休斯頓開設了一家新的最先進設施。
位於聖安東尼奧的新CRYOGENE生物庫已開始運營，爲其首個重要臍帶血庫客戶提供服務。
公司在第三季度繼續獲得動力，已簽署了九份價值超過600萬美元的高價值合同。
Opportunities:
機會：
Cryoport's Life Sciences Services is expected to see ongoing growth, particularly driven by the expanding market for cell and gene therapies.
Cryoport is well-positioned to capitalize on growing demand for biopharma supply chain solutions, projecting further revenue increases from newly commercialized therapies.
cryoport的生命科學服務預計將持續增長，特別受到細胞和基因療法市場擴大的推動。
cryoport處於有利地位，能夠利用生物製藥供應鏈解決方案需求增長，預計能從新商業化療法中進一步增加收入。
Risks:
風險：
Continued market challenges in the Life Sciences Product business, with product demand remaining subdued.
The cryogenic systems market, particularly MVE Biological Solutions, faces a slow recovery and unpredictable demand patterns.
生命科學產品業務仍面臨持續的市場挑戰，產品需求仍然低迷。
低溫系統市場，特別是MVE生物解決方案，面臨緩慢復甦和需求模式不確定性。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
